Manila Times Business
Kalaris to Present at Clinical Trials at the Summit 2026
BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degeneration
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Genesis Wins Best Fixed Income Trading Solution
1h ago
Veyond Metaverse Closes Strategic Investment from Japan-Based Private Investor as Global Commercial Momentum Accelerates Across Its XR Medical Telepresence Platform
1h ago
EXL and Databricks expand collaboration to help enterprises build trusted data foundations for AI
1h ago
BlockchAIn Announces Preliminary Inclusion in Russell Microcap® Index
1h ago